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Cytokine release syndrome (CRS) represents a life‐threatening side effect after 
haploidentical stem cell transplantation (Haplo‐SCT) with posttransplant cyclo-
phosphamide (PT‐Cy). Factors predictive of CRS development is still a matter of 
debate. We retrospectively analyzed 102 consecutive patients receiving a bone mar-
row (BM) (n = 42) or peripheral blood stem cells (PBSC) (n = 60) Haplo‐SCT 
with PT‐Cy. The two cohorts were similar in main patients’ characteristics besides 
disease type (P = .02). Cumulative incidence of grades 1, 2, and ≥3 CRS was 80%, 
52%, and 15% at a median of 2, 4, and 7 days, respectively. Moderate/High‐grade 
fever (39°‐41°), grade 1 and grade ≥3 CRS occurred more frequently after PBSC 
relative to BM grafts (68% vs 33%, P =  .0005; 87% vs 71%, P =  .009; 20% vs 
7%, P = .07). Only patients experiencing grade ≥3 CRS had a worse outcome in 
terms of 1‐year overall survival (OS) and nonrelapse mortality (NRM): 39% vs 80% 
(P = .002) and 40% vs 8% (P = .005), respectively. By univariate analysis the only 
factors associated with the increased risk of ≥3 CRS were pretransplant disease 
status (8% for complete remission, 11% for partial remission, and 38% for active 
disease, P = .002), HLA‐DRB1 mismatching (57% vs 14%, P = .007), and PBSC 
graft (P = .07). By multivariable analysis, only pretransplant disease status (hazard 
ratio, HR: 6.84, P = .005) and HLA‐DRB1 mismatching (HR: 17.19, P = .003) re-
mained independent predictors of grade ≥3 CRS. Only grade ≥3 CRS is clinically 
relevant for the final outcome of patients receiving Haplo‐SCT with PT‐Cy, is more 
frequent after a PBSC graft and is associated with pretransplant active disease and 
HLA‐DRB1 mismatching.
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1 |  INTRODUCTION
T‐cell‐replete haploidentical stem cell transplantation 
(Haplo‐SCT) with high‐dose posttransplant cyclophospha-
mide (PT‐Cy) represents an emerging alternative option for 
patients with hematologic malignancies when a HLA iden-
tical sibling or a matched related donor is not available.1,2 
Bone marrow (BM) stem cells represented the first type of 
graft used for Haplo‐SCT,3 but peripheral blood stem cells 
(PBSC) are more often employed because of the ease and 
convenience of collection.2
Cytokine release syndrome (CRS) is a potentially life‐
threatening toxic effect of immunotherapy and was first de-
scribed after treatment with blinatumomab4 or with chimeric 
antigen receptor (CAR)‐modified T cells.5,6 CRS results from 
the activation and cytotoxic‐mediated damage of monocytes, 
macrophages, and different lymphocyte populations with a 
massive release of inflammatory cytokines, including IL‐6, 
IFNγ, and IL‐2. CRS occurs as a systemic inflammation 
with a variety of symptoms ranging from nonspecific and 
not life‐threatening symptoms, such as fever, rigors, malaise, 
headaches, myalgias, arthralgias, vascular leak, hypotension, 
to more severe organ dysfunction like respiratory and renal 
insufficiency until multisystem organ failure.
More recently, a haplo‐immuno storm similar to CRS oc-
curring within the first 14 days after PBSC Haplo‐SCT with 
PT‐Cy was described by Abboud et al.7 Severe CRS was as-
sociated with poor clinical outcomes, including nonrelapse 
mortality (NRM), overall survival (OS), and delayed neutro-
phil and platelet engraftment. While Abboud et al7 could not 
identify any predictive factors associated with the increased 
risk of CRS, Raj et al8 described a higher incidence of grade 
≥2 CRS after PBSC relative to BM grafts. Fever is the most 
common manifestation of CRS and several reports have con-
sistently described the occurrence of a noninfectious fever 
within the first 5 days after Haplo‐SCT.9-14 This process was 
firstly called infusion‐related febrile reaction and was found 
to be associated with a higher risk of engraftment syndrome 
and acute graft‐vs‐host‐disease (aGVHD).12,13 Early post‐
SCT fever correlated with the dose of CD34+ cells content of 
the graft12,13 and more recently with the HLA II mismatching 
and myeloablative conditioning regimen.15
Here we report a retrospective study performed at our in-
stitution with the aim of investigating the outcome and risk 
factors of patients with CRS after Haplo‐SCT with PT‐Cy. 
We first hypothesize that patients receiving PBSC grafts 
were at higher risk of developing severe CRS relative to BM 
grafts and we aimed at comparing these two cohorts. We also 
analyze whether other variables, including HLA mismatch-
ing, may correlate with an increased risk of CRS.
2 |  PATIENTS AND METHODS
This is a retrospective study comprising 102 consecutive 
patients with hematologic malignancies receiving T‐cell‐re-
plete Haplo‐SCT with PT‐Cy at a single institution between 
January 2014 and December 2017. The study was approved 
from the Institutional Review Board at our institution and 
patients provided informed consent for the retrospective col-
lection of their data. All procedures followed were in accord-
ance with the ethical standards of the responsible committee 
on human experimentation (institutional and national) and 
with the Helsinki Declaration of 1975, as revised in 2008. 
Patients were ineligible for allogeneic transplant if they had 
active uncontrolled infections, a CNS disease, a Karnofsky 
performance status <60 or severe organ dysfunction, includ-
ing a left ventricular ejection fraction <40%, DLCO <50% 
or creatinine clearance <50 mL/min. The comorbidity index 
of each patient was calculated using the hematopoietic cell 
transplant‐comorbidity index (HCT‐CI) system.16
2.1 | Conditioning regimen and GVHD 
prophylaxis
Three different conditioning regimens prior to Haplo‐SCT 
were employed: (a) Cy 14.5  mg/kg on days −6 and −5, 
fludarabine 30 mg/m2 from day −6 to day −2 and low‐dose 
TBI (2  Gy) on day −1; (b) thiotepa 10  mg/kg on day −5, 
cyclophosphamide 30 mg/kg on day −4 and −3, fludarabine 
30 mg/m2 on day −4 and −3; (c) thiotepa 5 mg/kg on day‐5, 
fludarabine 50 mg/m2 from day −4 to day −2, busulphan iv 
3.2 mg/kg on day −4 and −3. GVHD prophylaxis consisted 
of posttransplantation Cy 50  mg/kg (PT‐Cy) administered 
on day +3 and +4, tacrolimus or cyclosporine A and my-
cophenolate mofetil as previously described.17 Granulocyte 
colony‐stimulating factor (G‐CFS) was started on day +5 in 
all patients as previously described.17
2.2 | Stem cell sources and donors
Potential family members were typed at the HLA‐A, HLA‐B, 
and HLA‐DRB1 loci at high level of resolution. Selected do-
nors were also typed at the HLA‐C locus at a high‐resolu-
tion level. Some donors underwent BM harvest under general 
anesthesia for a target dose of 3‐4 × 108 nuclear cells/kg of 
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recipient weight. Other donors were mobilized by the sub-
cutaneous administration of G‐CFS for 5‐6  days at 10  μg/
kg/day. The target was a minimum of 4 × 106 CD34 cells/
kg. Unmanipulated BM and PBSC were used for stem cell 
support on day 0. The choice of type of graft was related to 
physician or donor preference, therefore the was no particular 
bias due to graft type.
2.3 | Supportive care, engraftment, and 
GVHD evaluation
Supportive care was provided as described previously.17 
Neutrophil engraftment was defined as the first of 3 consecu-
tive days with an absolute neutrophil count of 0.5 × 109/L 
after transplantation. Platelet engraftment was defined as 
a platelet count of 20 × 109/L, with no transfusions during 
the preceding 7 days. aGVHD was graded according to the 
Keystone criteria,18 and chronic GVHD (cGVHD) following 
the National Institutes of Health criteria.19
2.4 | CRS definition
CRS was graded according to the original criteria from Lee et 
al20 and the recent update by Abboud et al7 in order to com-
prise also altered mental status and new onset cardiomyopa-
thy (Table S1). Symptoms occurring before day +14 were 
included as in the manuscript by Abboud et al7 and Raj et 
al.8 The detailed clinical data from posttransplantation days 
0‐14 were collected and used to grade CRS. These data in-
cluded fever curves, vital signs, renal and hepatic function 
tests, CRP levels, the development of vasopressor depend-
ence, oxygen requirement, and the need for mechanical ven-
tilation. Pre‐ and posttransplantation ejection fractions from 
echocardiogram and or nuclear perfusion study results were 
also collected. Patients with a documented infection did not 
receive a CRS grade. CRS was distinguished from engraft-
ment syndrome, which can also present as noninfectious 
fever and capillary leak, by onset before day +14 and the 
absence of skin rash.
2.5 | Statistical analysis
Categorical variables are expressed as number and propor-
tion, and continuous variables are expressed as median and 
range. For the calculation of CRS, documented infections 
were considered as competing event. For the calculation of 
NRM, disease relapse or progression was treated as a com-
peting event, whereas NRM was the competing event for the 
calculation of cumulative incidence of relapse or progres-
sion.21 The cumulative incidence of aGVHD was estimated 
considering death not related to aGVHD within a year post-
transplant as a competing event. cGVHD was estimated only 
for patients alive at day +100, considering death not related to 
cGVHD within 2 years posttransplant as a competing event. 
The Kaplan‐Meier method was used for the OS analysis.22 
Comparisons between groups were made using log‐rank and 
Gray tests when indicated. Cox regression (Cox) was per-
formed to identify any significant association between the 
main risk factors and the outcomes of interest23; variables 
with a P  <  .20 entered in the multivariable analysis and 
only those with a P ≤ .05 were retained in the final model. 
SPSS version 19.0 (IBM) and EZR (“Easy R”; R Institute for 
Statistical Computing) were used.
3 |  RESULTS
From February 2014 to December 2017, 102 consecutive pa-
tients received a Haplo‐SCT either from a BM (n = 42) or 
PBSC (n = 60) graft source. Median follow‐up time for alive 
patients was 26.8 months (range 5‐58). Patients’ characteris-
tics are summarized in Table 1. The two cohorts were similar 
in terms of median donor and recipient age, pretransplant dis-
ease status, CMV serostatus, HCT‐CI, conditioning regimen, 
donor/recipient relationship, and sex mismatch. The only dif-
ference was represented by disease type with acute myeloid 
leukemia/myelodysplastic syndrome as the most frequent 
malignancy among PBSC graft recipient (50%) and Hodgkin 
(HL: 36%) and non‐Hodgkin (NHL: 29%) lymphomas as the 
most frequent malignancy in the BM cohort (P = .02).
3.1 | Incidence and characteristics of CRS
Eighty‐two patients experienced grade 1 CRS at a me-
dian of 2 days (range 0‐14) post‐SCT, 53 had grade 2 CRS 
at a median of 4  days (range 0‐10), and 15 had grade ≥3 
CRS at a median of 7  days (range 0‐14) post‐SCT (Table 
2). Cumulative incidence of grades 1, 2, and ≥3 CRS was 
80% (95% confidential interval [CI]: 71‐87), 52% (95% CI: 
42‐61), and 15% (95% CI: 9‐22), respectively (Figure 1A, 
C, and E). Cumulative incidence of grades 1 and 3 CRS was 
higher after PBSC relative to BM grafts recipients (87% vs 
71%, P = .009 and 20% vs 7%, P = .07), while there was no 
difference in terms of grade 2 CRS between the two stem cell 
sources (58% vs 43%, P = .15) (Figure 1B, D, and F).
Signs and symptoms of CRS are summarized in Table 
3. Thirteen patients had positive blood cultures before 
any sign of CRS and were considered as competing event 
for the analysis. Seven patients had no fever. Fever was 
the most frequent event (82 patients, grade 1 CRS) with 
more patients experiencing low‐grade fever (<38°C) after 
BM Haplo‐SCT, and more patients with intermediate 
(38‐39°C) and high‐grade fever (>40°C) after PBSC trans-
plant (P = .0005). Hypotension and liver toxicity were the 
other more frequent manifestations of CRS with no dif-
ference between PBSC and BM grafts. Thirteen patients 
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required oxygen supply and 15 had altered mental status: 
both side effects were more frequent after PBSC Haplo‐
SCT. In particular, only PBSC recipients required higher 
volumes of oxygen supply (>3  L/min) relative to BM 
transplants (5 vs 0).
3.2 | Outcomes after Haplo‐SCT and CRS
One‐year OS and NRM rates for the whole population were 
68% (95% CI: 58‐77) and 19% (95% CI: 12‐27), respectively. 
Six‐month cumulative incidence of grade 2‐4 aGVHD and 
Characteristics Total PBSC graft BM graft P
No. patients 102 60 42  
Median recipient age 52 (20‐72) 56 (20‐72) 48 (22‐70) .08
Median donor age 41 (18‐71) 41 (18‐71) 38 (20‐67) .78
Gender M/F 46/56 35/25 21/21 .42
Disease type       .02
AML/MDS 39 (38%) 30 (50%) 9 (21%)
ALL 6 (6%) 3 (5%) 3 (7%)
Myeloproliferative 2 (2%) 2 (3%) 0
HL 30 (30%) 16 (27%) 15 (36%)
NHL 19 (19%) 7 (12%) 12 (29%)
Other 
lymphoproliferative
5 (5%) 2 (3%) 3 (7%)
Disease status pre‐Allo       .18
CR 63 (62%) 35 (58%) 28 (67%)
PR 18 (17%) 9 (15%) 9 (21%)
SD/PD 21 (21%) 16 (27%) 5 (12%)
Conditioning regimens       .61
Nonmyeloablative 35 (34%) 23 (38%) 12 (29%)
Reduced intensity 53 (52%) 29 (48%) 24 (57%)
Myeloablative 14 (14%) 8 (14%) 6 (14%)
HCT‐CI N = 100 N = 59 N = 41 .68
0‐2 53 (53%) 30 (51%) 23 (56%)
≥3 47 (47%) 29 (49%) 18 (44%)
CMV serostatus N = 100 N = 59 N = 41 98
Neg/Neg 4 (4%) 2 (4%) 2 (5%)
Pos/Neg 15 (15%) 9 (15%) 6 (15%)
Pos/Pos 64 (64%) 38 (64%) 26 (63%)
Neg/Pos 17 (17%) 10 (17%) 7 (17%)
Gender mismatch       .08
Female→male 21 (21%) 16 (26%) 5 (12%)
Others 81 (81%) 44 (74%) 37 (88%)
Donor type       .62
Child 40 (39%) 25 (42%) 15 (36%)
Sibling 45 (45%) 27 (46%) 18 (43%)
Parent 14 (13%) 6 (9%) 8 (19%)
Cousin/nephew 3 (3%) 2 (3%) 1 (2%)
Values are bold when P is statisctically significant (P < .05).
Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; BM, bone marrow; CMV, 
cytomegalovirus; CR, complete remission; HCT‐CI, hematopoietic cell transplant‐comorbidity index; HL, 
Hodgkin lymphoma; M/F, male/female; MDS, Myelodysplastic syndrome; NHL, non‐Hodgkin lymphoma; 
PBSC, peripheral blood stem cell; PD, progressive disease; PMF, primary myelofibrosis; PR, partial remission; 
SCT, stem cell transplantation; SD, stable disease.
T A B L E  1  Characteristics of patients 
receiving haploidentical‐SCT from a BM or 
PBSC graft
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2‐year moderate‐severe cGVHD were 29% (95% CI: 20‐38) 
and 8.5% (95% CI: 4‐15), respectively.
While OS and NRM did not differ between patients ex-
periencing grade ≥2 CRS vs grade <2 (data not shown), the 
outcome of recipients with grade ≥3 CRS was significantly 
worse compared with grade <3 CRS: 1‐year OS was 39% (95% 
CI: 15‐62) vs 80% (95% CI: 69‐88) (P = .002, Figure 2A), 1‐
year NRM was 40% (95% CI: 15‐64) vs 8% (95% CI: 3‐16) 
(P = .005, Figure 2B).
By univariate analysis, the other variables affecting OS and 
NRM were represented by pretransplant disease status (Table 4) 
and recipient age (1‐year OS, hazard ratio [HR]: 1.02, P = .02; 
1‐year NRM, HR: 1.03, P = .04, data not shown). Of note, NRM 
was much higher after PBSC relative to a BM graft, but this differ-
ence did not reach a statistical significance (20% vs 3%, P = .07).
Day 30 neutrophil engraftment did not differ between 
CRS ≥3 vs 2 vs patients with no CRS: 97% vs 100% vs 100% 
(P  =  .86). Grade 2‐4 aGVHD occurred more frequently 
among patients with grade 2 and grade ≥3 CRS relative to 
no CRS (36% vs 33% vs 14%), but the difference was not 
statistically significant (P  =  .38). Cumulative incidence of 
moderate‐severe cGVHD was higher after grade 2 or ≥3 CRS 
relative to no CRS (7% vs 13% vs 0%), but did not reach sta-
tistical significance (P = .37).
3.3 | Risks factors for CRS
Because severe CRS ≥3 was the only type of CRS affecting the 
final outcome, we restricted our analysis only to identify risk 
factors for severe CRS. By univariate analysis, variables asso-
ciated with increased incidence of grade ≥3 CRS were (Table 
4): pretransplant disease status (38% for patients in stable [SD] 
or progressive disease [PD] vs 11% for those in partial remis-
sion vs 8% for those in complete remission [CR]; P =  .002), 
graft source (PBSC vs BM: 20% vs 7%, P =  .07), and HLA 
class II DRB1 mismatching in the GVHD direction (57% vs 
14%, P = .007). Of note, neither recipient or donor age (data 
not shown), nor HLA mismatching in the GVHD direction on 
class I and other class II loci or CD34 cell dose were predictive 
risk factors for severe CRS (Table 4). By multivariable analysis 
(Table S2), active pretransplant disease (SD/PD) relative to CR 
status and HLA‐DRB1 mismatching in the GVHD direction re-
mained independent predictors for increased risk of grade ≥3 
CRS (HR: 14.3, P = .001, and HR: 17.2, P = .003, respectively).
T A B L E  2  CRS grading in PBSC and BM Haplo‐SCT
Days 0‐14 PBSC (n = 60) BM (n = 42) P
All grades 55 (92%) 33 (79%) .08
Grade 1 52 (87%) 30 (71%) .07
Grade 2 35 (58%) 18 (43%) .15
Grade 3‐4 12 (20%) 3 (7%) .09
Abbreviations: BM, bone marrow; CRS, cytokine release syndrome; PBSC, 
peripheral blood stem cell; Haplo‐SCT, haploidentical stem cell transplantation.
F I G U R E  1  Cumulative incidence 
of CRS after Haplo‐SCT with PT‐Cy: (A) 
Cumulative incidence of grade 1 CRS in 
the whole population; (B) after PBSC or 
BM grafts; (C) Cumulative incidence of 
grade 2 CRS in the whole population; (D) 
after PBSC or BM grafts; (E) Cumulative 
incidence of grade ≥3 CRS in the 
whole population; and (F) after PBSC 
or BM grafts. BM, bone marrow; CRS, 
cytokine release syndrome; Haplo‐SCT, 
haploidentical stem cell transplantation; 
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4 |  DISCUSSION
In this report we have confirmed that grade ≥3 CRS is associ-
ated with a worse outcome in patients receiving Haplo‐SCT 
with PT‐Cy both in terms of OS and NRM. Our results ex-
tends previous observations on risk factors for the develop-
ment of life‐threatening CRS since we have identified that 
disease burden (pretransplant active disease), HLA‐DRB1 
mismatching, and graft type (PBSC vs BM) were signifi-
cantly associated with a higher incidence of grade ≥3 CRS.
CRS has been described as a life‐threatening side ef-
fect not only after CAR‐T cells or bispecific antibodies5,6 
but recently also after Haplo‐SCT with PT‐Cy as GVHD 
prophylaxis.7 A similar finding was reported by Raj et 
al8 that did not find a statistically significant associa-
tion between NRM and grade ≥2 CRS, but a tendency of 
greater NRM for grade ≥3 CRS by multivariable analy-
sis. Consistent with these observations, we have found that 
grade ≥3 CRS, but not grade 2 CRS, was associated with 
worse OS (39% vs 80%, P = .002) and NRM (40% vs 8%, 
P  =  .005; Figure 2). Similar to Abboud et al,7 only one 
death in our cohort was directly attributable to CRS, while 
the increased death rate for patients with grade ≥3 CRS 
was due to other causes not directly correlated with CRS. 
This implies, as observed by Abboud et al,7 that CRS in the 
immediate posttransplantation setting may have long‐term 
Characteristics All PBSC (n = 60) BM (n = 42) P
No fever 7 3 (5%) 4 (10%) .0005
Fever      
38‐39 31 11 (19%) 20 (48%)
39‐40 30 24 (40%) 6 (13%)
>40 21 17 (28%) 4 (10%)
Positive blood cultures 13 5 (8%) 8 (19%)  
Hypotension (requiring fluids)       .17
None 65 34 (56%) 31 (74%)
Low dose pressure 35 25 (42%) 10 (24%)
High dose pressures 2 1 (2%) 1 (2%)
O2 requirement   8 (13%) 5 (12%) .08
Nasal cannula ≤3 L/min 8 3 (5%) 5 (12%)
Nasal cannula >3 L/min 5 5 (8%) 0
Renal failure   9 (15%) 9 (21%) .44
Grade 1 10 4 (7%) 6 (14%)
Grade 2 8 5 (8%) 3 (7%)
Liver failure   25 (42%) 16 (38%) .82
Grade 2 25 16 (27%) 9 (21%)
≥ Grade 3 16 9 (15%) 7 (17%)
Altered mental status 15 12 (20%) 3 (7%) .09
Values are bold when P is statisctically significant (P < .05).
Grading was assessed according to CTCAE v4.0 grading.
Abbreviations: BM, bone marrow; CRS, cytokine release syndrome; Haplo‐SCT, haploidentical stem cell 
transplantation; PBSC, peripheral blood stem cell.
T A B L E  3  Characteristics of CRS in 
BM or PBSC Haplo‐SCT
F I G U R E  2  A, One‐year OS for 
CRS ≥3 vs <3 after Haplo‐SCT with 
PT‐Cy. B, One‐year NRM for CRS ≥3 vs 
<3 after Haplo‐SCT with PT‐Cy. CRS, 
cytokine release syndrome; Haplo‐SCT, 
haploidentical stem cell transplantation; 
NRM, nonrelapse mortality; OS, 
overall survival; PT‐Cy, posttransplant 
cyclophosphamide
A B
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side effects outside the time window of CRS occurrence 
(ie, day 0‐14). Similar to Abboud,7 we have identified a 
tendency for an increased incidence of aGVHD after grade 
2 or ≥3 CRS, but GVHD alone does not explain alone the 
higher NRM rate within this cohort. This may be due to 
other mechanisms related to the cytokine storm, such as en-
dothelial damage or macrophage activation. Unfortunately, 
we were not able to quantify cytokine storm and markers of 
endothelial damage due to the retrospective nature of our 
study. It is important to note that also patients receiving 
Characteristics CI CRS 3‐4 P 1y‐NRM P 1 y‐OS P
Disease type   .59   .16   .09
Myeloid 17% (7‐30) 17% (7‐31) 65% (47‐79)
Lymphoid 13% (6‐23) 12% (5‐22) 79% (65‐88)
Disease status 
pre‐Allo
  .002   .64   .0002
CR 8% (3‐16) 9% (3‐19) 85% (73‐92)
PR 11% (2‐30) 25% (7‐48) 63% (35‐81)
SD/PD 38% (18‐58) 18% (4‐39) 45% (21‐67)
Conditioning   .99   .76   .44
Nonmyeloblative 14% (5‐28) 16% (6‐31) 74% (55‐86)
RIC 15% (7‐26) 14% (6‐27) 69% (52‐81)
MAC 14% (2‐38) 10% (0‐37) 80% (41‐95)
HCT‐CI   .39   .17   .65
0‐2 11% (5‐22) 7% (2‐17) 73% (58‐84)
>3 17% (8‐29) 22% (11‐36) 75% (59‐86)
CMV serostatus   .67   .71   .09
Neg→Pos 12% (2‐32) 14% (2‐38) 86% (54‐96)
Others 16% (9‐24) 14% (0‐23) 71% (59‐80)
Gender D/R   .48   .97   .79
Female→male 19% (6‐38) 13% (2‐34) 68% (40‐85)
Others 14% (7‐22) 14% (7‐23) 75% (63‐83)
Graft source   .07   .07   .63
BM 7% (2‐18) 3% (0‐14) 78% (59‐89)
PBSC 20% (11‐31) 20% (11‐32) 71% (57‐81)
HLA   .31   .67   .67
No 12% (6‐21) 76% (63‐85) 76% (63‐85)
GVHD 21% (8‐37) 67% (44‐82) 67% (44‐82)
HLA   .34   .65   .64
No 19% (9‐27) 73% (60‐83) 73% (60‐83)
HVG 9% (2‐23) 74% (53‐87) 74% (53‐87)
HLA‐GVHD   .007   .72   .83
No DRB1 14% (6‐21) 74% (62‐82) 14% (7‐22)
DRB1 GVHD 57% (0‐82) 71% (26‐92) 14% (0‐50)
CRS   NA   .005   .002
0‐2 NA 8% (3‐16) 80% (69‐88)
≥3   40% (15‐64) 39% (15‐62)
Values are bold when P is statisctically significant (P < .05).
Abbreviations: BM, bone marrow; CI, cumulative incidence; CMV, cytomegalovirus; CR, complete remission; 
CRS, cytokine releasing syndrome; GVHD, graft‐vs‐host‐disease; Haplo‐SCT, haploidentical stem cell 
transplantation; HCT‐CI, hematopoietic cell transplant‐comorbidity index; MAC, myeloablative conditioning; 
NRM, nonrelapse mortality; OS, overall survival; PBSC, peripheral blood stem cell; PD, progressive disease; 
PR, partial remission; RIC, reduced intensity conditioning; SD, stable disease.
T A B L E  4  Univariate analysis of the 
outcome of patients receiving PBSC Haplo‐
SCT for CRS ≥3, NRM and OS
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a PBSC graft were at higher risk of NRM relative to pa-
tients transplanted with a BM graft, but this difference did 
not reach statistical significance probably due to our small 
sample size. This may be due to the higher incidence of 
grade ≥3 CRS or other complication, such as GVHD as 
recently reported by retrospective studies.24,25
The most common manifestation of CRS is represented 
by a noninfectious fever, that was originally named IFRT, 
occurring in the very first days after T‐cell‐replete Haplo‐
SCT with PT‐Cy in approximately 30%‐90%11-13 of the cases 
and usually resolving 24 hours after the last dose of cyclo-
phosphamide without any steroid treatment.14 More recently, 
McCurdy et al15 reported an incidence of early fever of 53% 
after Haplo‐SCT using BM as graft source. The authors re-
ported a very low NRM rate, ranging between 8% and 14% 
depending on the intensity of the conditioning regimen. 
Cumulative incidence of grade 1 CRS was higher in our study 
because most of our patients received PBSC instead of BM 
as graft source and also because CRS was followed up to day 
14 as in Abboud7 report, instead of day 6 as in the study by 
McCurdy et al.15 When we considered grade 1 CRS occur-
ring within day 6 post‐SCT, 57% of the patients transplanted 
with BM (data not shown) experienced early fever similar to 
McCurdy et al.15 Consistent with the findings from the John 
Hopkins group, grade 1 CRS was not significantly associated 
with different OS (73% vs 71%, P = .69) and NRM (16% vs 
14%, P = .71).
Frequency of grade ≥3 CRS was similar in our cohort 
(15%) to previous findings by Abboud et al (12%)7 and Raj et 
al (11%).8 Our study not only confirms, but extends previous 
reports on risk factors contributing to the occurrence of se-
vere CRS. While the study from the Washington University 
of St Louis7 did not identify any risk factors, Raj et al8 
demonstrated a higher incidence and severity of CRS after 
PBSC relative to BM cells. In this study we confirmed these 
observations, since recipients of PBSC grafts were at higher 
risk of developing high fever for grade 1 CRS (P = .0005). 
Moreover, grade ≥3 CRS was three times more frequent 
after PBSC relative to a BM graft (P = .07). This observa-
tion may suggest that T or CD34+ cell doses are central me-
diators of CRS, but neither Abboud7 nor Raj8 were able to 
correlate the severity of CRS with T or CD34+ contents of 
the graft. In marked contrast, McCurdy et al15 identified a 
strong correlation between early fever and CD3+ cell content. 
Unfortunately, we were not able to correlate the incidence of 
CRS with CD3+ cell content of the graft due to missing data. 
In any case, we did not see any association between CD34+ 
cell dose and grade ≥3 CRS. This suggests the importance 
of other factors that may mediate CRS, such as HLA‐DRB1 
mismatching and tumor burden that we were able to iden-
tify for the first time as variables associated with grade ≥3 
CRS in the contest of Haplo‐SCT with PT‐Cy. McCurdy et 
al15 reported for the first time a correlation between class II 
HLA mismatching and early fever after Haplo‐SCT. In agree-
ment with this finding we observed that HLA mismatching 
at the DRB1 locus in the GVHD direction was associated 
with higher incidence of grade ≥3 CRS, suggesting an im-
portant role for CD4+ cells and class II HLA‐mediated pre-
sentation in the pathophysiology of CRS. Unfortunately, 
data relative to HLA DPB1 mismatching were not available 
in our study. Another interesting finding of this report is the 
increased incidence of grade ≥3 CRS for patients with high 
tumor burden. This observation is an agreement with several 
reports showing that disease burden is among the most im-
portant predictors of severe CRS after CAR‐T cell therapy 
or bispecific T‐cell engager administration.26-29 All together 
these observations may help identify patients at higher risk 
for life‐threatening CRS and develop models for prevention 
(such as BM graft for patients with active disease status or 
class II HLA mismatch) or early intervention (for instance, 
with anti‐IL6 antibody) at the first signs of CRS in patients at 
higher risk of CRS. In this contest, tocilizumab has recently 
emerged has a promising therapy for patients with CRS after 
Haplo‐SCT.30,31 In our study, tocilizumab was employed only 
in one patient who eventually died of multiorgan failure on 
day 28 post‐SCT.
It is important to acknowledge the limitations of this 
study due to its retrospective nature, the limited number of 
patients, and the single‐center setting. The next step of our 
study is to participate to a multi‐center collaboration in order 
to confirm and extend our preliminary findings. This effort 
can be of translational relevance in order to develop a clinical 
trial for prevention or preemptive treatment of life‐threaten-
ing CRS in a cohort of patients at high risk to develop such 
complication. Deepening our understanding of CRS biology, 
by analyzing not only the T cell, but also the macrophage32 
and endothelial compartment, is warranted in order to im-
prove our chances to predict and abrogate CRS after T‐cell‐
replete Haplo‐SCT.
In summary, our analyses illustrate that grade ≥3 CRS is 
a life‐threatening side effect after Haplo‐SCT with PT‐Cy 
and that high tumor burden, class II HLA mismatching and 
graft source are important predictors of such complication. 
Therefore, selection of the best available donor, optimization 
of pretransplant tumor response and selection of the most ap-
propriate graft source are all important factors to take into 
consideration to optimize the outcome of patients receiving 
Haplo‐SCT with PT‐Cy.
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